Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFV890 plus standard of care for hospitalized COVID-19 pneumonia
NL-OMON49323Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus pneumonia comparing DFV890 plus standard of care with Standard of care alone (2 arms). Primary endpoint: APACHE II severity of disease score. Started Sep 2020; status: active, not recruiting.
02
Drugs
DFV890
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on NL-OMON49323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49323.